EUVIMEDEUVIMED entdecken
Crossref

In Vivo Metabolic Profiling of Suzetrigine in Thoroughbred Horses Following Oral Administration: Implications for Equine Anti‐Doping Control

Michael Benedict Subhahar iD, Moses Philip iD, Fatma Ibrahim Alhammadi iD, Tajudheen K Karatt iD, Samir Meissir iD, Zubair Perwad iD, Fatma Mohammed Graiban iD, Shino Ann Koshy iD, Meleparappil Muhammed Ajeebsanu iD, Abdul Khader Karakka Kal iD

Drug Testing and Analysis · 07.11.2026

DOI: 10.1002/dta.70186 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Testing and Analysis, online erschienen am 07.11.2026. Verfasst von Michael Benedict Subhahar und 9 weiteren Autor:innen. Beteiligte Einrichtung: Equine Forensic Unit, Central Veterinary Research Laboratory, Dubai, UAE. Die Arbeit nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Suzetrigine (VX‐548), a selective NaV1.8 sodium channel blocker recently approved for pain management, was investigated for its metabolic fate in Thoroughbred horses using liquid chromatography coupled to high‐resolution mass spectrometry (LC‐HRMS). Equine urine and plasma samples were collected following administration and processed prior to analysis. Combining the present in vivo data with earlier reported in vitro liver incubations, a total of 12 metabolites ( M1 – M12 ) were identified and characterised, comprising nine Phase I and three Phase II biotransformation products. Five Phase I metabolites ( M1 – M4 and M9 ) were detected in vivo, formed through O‐demethylation, C‐demethylation, monohydroxylation, and hydrolysis of the amide function. Four further Phase I metabolites ( M5 – M8 ), previously reported by our team, were observed solely in in vitro liver incubations and were not detected in any in vivo sample. Phase II metabolism yielded three conjugated metabolites, comprising two glycosidation products ( M10 and M11 ) detected in both urine and plasma, and one sulfonate conjugate ( M12 ) confined to urine. Intact suzetrigine was the most abundant plasma analyte at every sampling point, followed by the O‐demethylated metabolite M1 , whereas in urine, the amide hydrolysis product M9 was overwhelmingly dominant and the parent drug accounted for less than 1% of its response. Intact suzetrigine remained detectable in plasma throughout a 192‐h period, while M1 and M9 persisted in urine to the final sampling points. These findings define the metabolic disposition of suzetrigine in the horse and identify M9 and M1 as the most suitable analytical targets for the detection of suzetrigine misuse in equine doping control.

Schlagwörter

Stichwörter der Autor:innen

LC‐HRMS analysisNaV1.8 inhibitorVX‐548anti‐dopingequine metabolismin vivosuzetrigine

Autor:innen und Institutionen

  • Equine Forensic Unit, Central Veterinary Research Laboratory, Dubai, UAE.

ORCID-Profile: Michael Benedict Subhahar, Moses Philip, Fatma Ibrahim Alhammadi, Tajudheen K Karatt, Samir Meissir, Zubair Perwad, Fatma Mohammed Graiban, Shino Ann Koshy, Meleparappil Muhammed Ajeebsanu, Abdul Khader Karakka Kal

Zitieren

APA

Subhahar, M. B., Philip, M., Alhammadi, F. I., Karatt, T. K., Meissir, S., Perwad, Z., Graiban, F. M., Koshy, S. A., Ajeebsanu, M. M., & Kal, A. K. K. (2026). In Vivo Metabolic Profiling of Suzetrigine in Thoroughbred Horses Following Oral Administration: Implications for Equine Anti‐Doping Control. Drug Testing and Analysis. https://doi.org/10.1002/dta.70186

Vancouver

Subhahar MB, Philip M, Alhammadi FI, Karatt TK, Meissir S, Perwad Z, et al. In Vivo Metabolic Profiling of Suzetrigine in Thoroughbred Horses Following Oral Administration: Implications for Equine Anti‐Doping Control. Drug Testing and Analysis. 2026. doi:10.1002/dta.70186

BibTeX
@article{Subhahar2026,
  author = {Subhahar, Michael Benedict and Philip, Moses and Alhammadi, Fatma Ibrahim and Karatt, Tajudheen K and Meissir, Samir and Perwad, Zubair and Graiban, Fatma Mohammed and Koshy, Shino Ann and Ajeebsanu, Meleparappil Muhammed and Kal, Abdul Khader Karakka},
  title = {In Vivo Metabolic Profiling of Suzetrigine in Thoroughbred Horses Following Oral Administration: Implications for Equine Anti‐Doping Control},
  journal = {Drug Testing and Analysis},
  year = {2026},
  doi = {10.1002/dta.70186}
}
Kostenlos starten →